1. Home
  2. CDNA vs KLRA Comparison

CDNA vs KLRA Comparison

Compare CDNA & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$53.96

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Kailera Therapeutics Inc. Common Stock

KLRA

Kailera Therapeutics Inc. Common Stock

N/A

Current Price

$12.45

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CDNA
KLRA
Founded
1998
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.4B
IPO Year
2007
2026

Fundamental Metrics

Financial Performance
Metric
CDNA
KLRA
Price
$53.96
$12.45
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$28.00
N/A
AVG Volume (30 Days)
1.0M
735.1K
Earning Date
04-28-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.13
N/A
Revenue
$48,324,000.00
N/A
Revenue This Year
$16.01
N/A
Revenue Next Year
$11.31
N/A
P/E Ratio
$25.48
N/A
Revenue Growth
18.93
N/A
52 Week Low
$13.95
$12.47
52 Week High
$55.16
$23.82

Technical Indicators

Market Signals
Indicator
CDNA
KLRA
Relative Strength Index (RSI) 69.87 28.01
Support Level $45.74 N/A
Resistance Level N/A $19.15
Average True Range (ATR) 2.17 1.06
MACD -0.00 -0.29
Stochastic Oscillator 85.84 2.03

Price Performance

Historical Comparison
CDNA
KLRA

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About KLRA Kailera Therapeutics Inc. Common Stock

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

Share on Social Networks: